Open Dataset · DOI 10.5281/zenodo.24139315Published 2026-11-11 · Dallas, TX
Official Wire Archive · 35 Releases
4 CERN/Zenodo DOIs · 467 Clinical Cost Records
Losing Weight RX Pressroom, Wire Releases & Open-Data Media Kit
Official announcements, consumer fee watchdog investigations, and peer-verifiable pharmacoeconomic dataset releases from the Losing Weight RX Pharmacoeconomics & Consumer Audit Desk (Dallas, TX). Media & research inquiries: [email protected].
Permanent Open-Science Repository Citations (CC BY 4.0)
Official Wire Announcements (35 Releases)
Open Dataset · DOI 10.5281/zenodo.24139325Published 2026-11-11 · Dallas, TX
Losing Weight RX Releases 2026 Commercial Insurance GLP-1 Prior-Authorization Denial Study
Open Dataset · DOI 10.5281/zenodo.24139333Published 2026-11-11 · Dallas, TX
Losing Weight RX Audits Absorbed-Dose Economics Across Injectable, Oral, and IV Lounge NAD+ and Glutathione
Clinical Cost BenchmarkPublished 2026-11-11 · Dallas, TX
Losing Weight RX Publishes Comparative Cost and Absorption Benchmark for Needle-Free Sublingual GLP-1 Tablets
Open Dataset · DOI 10.5281/zenodo.24139340Published 2026-11-11 · Dallas, TX
Losing Weight RX Launches 50-State and D.C. Telehealth GLP-1 Prescribing Law and Medicaid Access Directory
Interactive Consumer ToolsPublished 2026-11-11 · Dallas, TX
Losing Weight RX Introduces Five Free Pharmacoeconomic Tools Including a U-100 Vial Unit Converter
Consumer Fee WatchdogPublished 2026-11-11 · Dallas, TX
Losing Weight RX Consumer Watchdog Report Exposes Telehealth Membership Dues and High-Dose Surcharges
Open Research PortalPublished 2026-11-11 · Dallas, TX
Losing Weight RX Establishes Open-Access Pharmacoeconomic Research Portal With 467 Verified Clinical Cost Records
Consumer Pricing AuditPublished 2026-11-09 · Dallas, TX
Losing Weight RX Analyzes Out-of-Pocket Expenditure Trends in Telehealth Weight Loss
HSA & FSA GuidePublished 2026-11-09 · Dallas, TX
Losing Weight RX Details HSA and FSA Reimbursement Strategies for Online Obesity Care
Regulatory AdvisoryPublished 2026-11-09 · Dallas, TX
Losing Weight RX Releases 2026 National Pharmacy Supply and Compounding Regulation Advisory
Clinical EducationPublished 2026-11-09 · Dallas, TX
Losing Weight RX Publishes Evidence-Based Protocol Guide for First-Time GLP-1 Patients
Fee WatchdogPublished 2026-11-09 · Dallas, TX
Losing Weight RX Evaluates Telehealth Subscription Fees Versus Flat-Rate Incretin Care
Telehealth OperationsPublished 2026-11-09 · Dallas, TX
Losing Weight RX Compares Virtual Consultation Standards and Pharmacy Delivery Speeds
Tirzepatide Cost AuditPublished 2026-11-09 · Dallas, TX
Losing Weight RX Issues 2026 Direct Sourcing and Cost Analysis for Compounded Tirzepatide
Provider ComparisonPublished 2026-11-09 · Dallas, TX
Losing Weight RX Releases Head-to-Head Out-of-Pocket Telehealth Price Comparison Report
Fee WatchdogPublished 2026-11-09 · Dallas, TX
Losing Weight RX Audits Digital Weight Loss Membership Dues and Hidden Surcharges for 2026
Semaglutide Cost AuditPublished 2026-11-09 · Dallas, TX
Losing Weight RX Publishes 2026 Direct Price Audit on Compounded Semaglutide Telehealth Providers
Longevity & RecoveryPublished 2026-11-07 · Dallas, TX
Losing Weight RX Publishes 2026 Black Friday Sermorelin Peptide Consultation and Wellness Guide
Seasonal Pricing ReportPublished 2026-11-07 · Dallas, TX
Losing Weight RX Releases Dual-Incretin Black Friday Consultation Report With Zero Subscription Club Dues
Fee TransparencyPublished 2026-11-07 · Dallas, TX
Losing Weight RX Publishes 2026 Black Friday Telehealth Consultation Directory and Fee Transparency Report
Cellular WellnessPublished 2026-11-07 · Dallas, TX
Losing Weight RX Publishes 2026 Black Friday Injectable Glutathione Report: Clinical Superiority Over Oral Supplements
Fee TransparencyPublished 2026-11-07 · Dallas, TX
Losing Weight RX Publishes 2026 Black Friday Telehealth Consultation Directory and Fee Transparency Report (Edition 1)
Consumer WatchdogPublished 2026-11-06 · Dallas, TX
Online Telehealth Red Flags: 7 Warning Signs of Deceptive Pricing and Hidden Recurring Fees
Retail Pharmacy CrisisPublished 2026-11-06 · Dallas, TX
Retail Brand Out-of-Pocket Crisis: Why $1,050/mo Ozempic and Mounjaro Drive Patients to Telehealth
Provider AuditPublished 2026-11-06 · Dallas, TX
Calibrate and WeightRx Review: Patient Sentiment Analysis on Customer Service Delays and Pharmacy Shortages
Dose-Escalation AuditPublished 2026-11-06 · Dallas, TX
Compounded Tirzepatide From 2.5mg to 15mg: Platforms That Don't Increase Price as Dose Doubles
Insurance AppealsPublished 2026-11-06 · Dallas, TX
Commercial GLP-1 Insurance Denial Toolkit: How to Appeal Prior Authorization Denials
Patient ContinuityPublished 2026-11-06 · Dallas, TX
Switching GLP-1 Providers: How to Transfer Prescriptions Without Being Forced Back to Starting Doses
Contract WarningPublished 2026-11-06 · Dallas, TX
Avoid 12-Month Upfront GLP-1 Contracts: Consumer Warning on Non-Refundable Telehealth Packages
Provider AuditPublished 2026-11-06 · Dallas, TX
OrderlyMeds vs Direct Telehealth: Delivery Velocity, Partner Pharmacies, and Total Annual Expense
Provider AuditPublished 2026-11-06 · Dallas, TX
Mochi Health Review: In-Depth Cost Analysis of Compounded Incretins Plus Subscription Dues
Provider AuditPublished 2026-11-06 · Dallas, TX
Hims & Hers Weight Loss Review: Real Patient Costs of Oral Compounded vs Injectable Options
Provider AuditPublished 2026-11-06 · Dallas, TX
Ro Body Membership Cost vs Direct Care: Analyzing the $1,200/Year Fee on Top of Medication
Fee WatchdogPublished 2026-11-06 · Dallas, TX